Every healthcare facility in America faces the same problem: regulated medical waste leaves the building, gets loaded onto a truck, driven across the state (or the country), and either incinerated or autoclaved at a centralized treatment plant. The waste is rendered non-infectious, but the material , millions of pounds of perfectly good plastic , goes to a landfill. The carbon footprint of that chain is enormous. The liability exposure while infectious waste is in transit is real. And the circularity is zero.
We decided to change that. In early 2026, BayArea Compliance installed the EnvoMed 80 on-site medical waste treatment system at our Fairfield, California facility. We are the first operation in the United States to deploy this technology as part of a full-cycle waste-to-virgin-plastic recycling program. Not just treatment. Not just disposal. Full circularity , from infectious medical waste back to virgin-grade plastic pellets that re-enter the supply chain.
This is the core of what NETZERO360 was built to do: close the loop on waste that everyone else treats as a one-way trip to a landfill.
What the EnvoMed 80 Actually Does
The EnvoMed 80 is an on-site medical waste treatment system developed by Maabarot Metal Works under the EnvoMed brand in Israel. It combines mechanical destruction with chemical disinfection in a single enclosed unit, processing 80 liters of infectious waste per cycle in approximately 15 to 18 minutes.
Here is what happens inside the machine during each cycle:
Mechanical destruction. A 4-shaft industrial shredder reduces all waste , sharps, syringes, bandages, gloves, plastic containers, dialysis filters , into small, confetti-like fragments. The output is completely unrecognizable, which matters both for regulatory compliance and for patient privacy. You cannot identify what the waste was after shredding.
Chemical sterilization. The shredded material is simultaneously treated with Biocetic 45, a proprietary disinfectant based on peracetic acid and hydrogen peroxide at 1% concentration. Biocetic achieves STAATT Level IV sterilization , the highest level defined under international STAATT (State and Territorial Association on Alternate Treatment Technologies) guidelines. Level IV means a minimum 6 LOG10 reduction of bacterial spores in both solid and liquid phases. That is a 99.9999% kill rate.
Safe output. The solid phase , shredded, sterilized fragments , is rendered non-infectious and can legally be disposed of as municipal solid waste. The liquid phase breaks down into water, oxygen, and acetic acid (vinegar), and can be safely discharged to standard sewage drainage. No toxic residuals. No secondary waste stream requiring special handling.
The entire process happens on-site. No transportation of infectious waste on public roads. No chain-of-custody handoffs between your facility and a distant treatment plant. No liability exposure during transit.
The Waste Types It Handles
The EnvoMed 80 is designed for the full spectrum of biohazardous medical waste that healthcare facilities generate daily:
- Sharps (needles, scalpel blades, lancets)
- Syringes (with or without needles attached)
- Plastic sharps containers (the red bins themselves)
- Bandages, dressings, and wound care materials
- Gloves, masks, gowns, and other PPE
- Dialysis filters and tubing
- Contaminated medical instruments
- Blood, urine, and stool samples
- Human tissue specimens
- IV bags and tubing
What it does not treat: The EnvoMed 80 is not designed for pharmaceutical chemicals, cytotoxic or chemotherapy waste, radioactive materials, large hard metal surgical instruments, or titanium items. These waste streams require separate handling under RCRA, NRC, or DEA regulations. We maintain separate compliant pathways for each of these at BAC , the EnvoMed handles the biohazardous stream specifically.
Why On-Site Treatment Changes Everything
The traditional medical waste disposal model has not fundamentally changed in 40 years. A permitted hauler drives to your facility on a schedule, picks up sealed containers of infectious waste, and transports them to a centralized treatment facility , which could be 50 miles away or 500 miles away. The waste is autoclaved (steam-sterilized under pressure) or incinerated.
Both legacy methods have serious drawbacks:
Autoclaving uses enormous amounts of energy to generate steam at 250 degrees Fahrenheit under 15 PSI for extended cycle times (often 60 to 90 minutes). The equipment is expensive, requires dedicated infrastructure, and the treated waste still goes to a landfill. Nothing is recovered.
Incineration eliminates the waste entirely but generates toxic air emissions, requires pollution control equipment, and destroys all recoverable material. It is the most carbon-intensive disposal method available.
On-site treatment with the EnvoMed 80 eliminates both the transportation chain and the energy-intensive treatment methods. No burning. No heat. No steam. No pressurized vessels. No odor. No noise beyond the shredding cycle. The disinfectant (Biocetic 45) works at ambient temperature. The room requirements are minimal: a ventilated space of approximately 3 by 5 meters with standard electricity, water supply, pressurized air, and floor drainage.
Treatment Technology Comparison
| Feature | EnvoMed 80 | Traditional Autoclave | Incineration |
|---|---|---|---|
| Treatment location | On-site | Centralized facility | Centralized facility |
| Cycle time | 15-18 minutes | 60-90 minutes | Continuous |
| Volume reduction | 80-90% | 15-25% | 95%+ (ash) |
| Sterilization level | STAATT Level IV (6 LOG10) | STAATT Level III-IV | Complete destruction |
| Energy source | Electricity only | Steam (gas/electric boiler) | Natural gas or diesel |
| Emissions | None | Steam exhaust | Toxic air emissions (dioxins, furans) |
| Noise | Low (enclosed shredder) | Moderate (steam release) | High (combustion) |
| Odor | None | Minimal | Significant |
| Material recovery | Yes , plastic recyclable | No , landfilled | No , ash disposal |
| Transportation required | None | Yes , licensed hauler | Yes , licensed hauler |
| Carbon footprint | Minimal | Moderate | Very high |
| Typical capital cost | $150K-$250K | $500K-$1M+ | $2M-$10M+ |
| Regulatory pathway | CDPH alternative treatment permit | Standard CDPH permit | Air quality permits + CDPH |
The comparison is not close. On-site chemical disinfection with the EnvoMed 80 achieves the highest sterilization standard at a fraction of the cost, energy, and emissions of legacy methods , and it is the only approach that preserves the material for downstream recycling.
The Full-Cycle Difference: From Waste to Virgin Plastic
This is the part that matters most to us, and it is what makes NETZERO360 fundamentally different from every other medical waste program in the country.
Most companies that sell on-site treatment systems stop at the sterilization step. The waste is shredded, sterilized, and then thrown away as municipal solid waste. Problem solved, from their perspective , the infectious risk is eliminated.
We do not stop there. The shredded, sterilized output from the EnvoMed 80 is the beginning of our recycling process, not the end.
Step 1: Shred and sterilize. The EnvoMed 80 processes the biohazardous waste into non-infectious fragments.
Step 2: Sort by resin type. Our team sorts the shredded plastic output by resin identification code using work instructions developed by Mike Tufu, our operations lead. Mike and Terrell Puckett trained on-site with the EnvoMed manufacturer for a full week when we installed the unit. The sorting process separates HDPE, LDPE, PP, PET, and other resin types into distinct streams.
Step 3: Send to recycling processors. The sorted resin streams go to domestic recycling processors who convert them into virgin-grade plastic pellets. Not downcycled. Not blended into lower-grade material. Virgin-grade pellets that meet the specifications for new product manufacturing.
Step 4: New products. Those pellets re-enter the supply chain as raw material for new plastic products , closing the loop completely.
This is what circular economy actually looks like in medical waste. Not carbon credits. Not offsets. Not "sustainability reports" built on industry averages. Physical material flowing from medical waste back into the manufacturing supply chain, tracked at every step with chain-of-custody documentation.
BAC orchestrates the entire chain: collection, on-site treatment, sorting, and recycling coordination. That is NETZERO360 , the full circularity platform, not just one step in the process.
Validated Results and Global Deployments
The EnvoMed 80 is not experimental technology. It has been validated in demanding clinical environments across multiple countries.
HUS Helsinki University Hospital (Finland) deployed the EnvoMed system and reported 30% cost savings compared to their previous off-site treatment arrangement. Helsinki is one of the largest academic medical centers in Northern Europe, generating significant volumes of infectious waste daily.
Takeda Climate Solutions Prize (2024). Takeda Pharmaceutical's BioLife plasma donation centers , operating 230-plus locations , challenged startups to solve their single-use plastic waste problem. The EnvoMed system won. That is a global pharmaceutical company with 230 centers saying this technology is the answer to their waste circularity challenge.
South Korea regulatory approval. The EnvoMed system has cleared the regulatory pathway in South Korea, opening the Asian healthcare market.
BayArea Compliance, Fairfield, California (2026). We are the first US deployment, and the first operation anywhere to integrate the EnvoMed 80 into a complete waste-to-virgin-plastic recycling workflow. The treatment unit is one piece. The sorting, recycling coordination, and chain-of-custody documentation are ours.
California Regulatory Context
California regulates medical waste under the Medical Waste Management Act (Health and Safety Code Sections 117600 through 118360). Section 117635 defines biohazardous medical waste , the category the EnvoMed 80 is designed to treat.
The California Department of Public Health (CDPH) permits alternative treatment technologies that meet STAATT Level III or Level IV sterilization standards. The EnvoMed 80 meets Level IV , the highest tier , making it eligible for CDPH alternative treatment permitting.
Cal/OSHA requirements for medical waste handling (Title 8, Section 5193 , Bloodborne Pathogens) still apply to the handling and loading of waste into the treatment unit. Our staff follows standard BBP protocols: PPE, engineering controls, exposure control plans, and annual training. On-site treatment does not eliminate workplace safety requirements , it eliminates the transportation and off-site processing risks.
For facilities considering on-site treatment, the regulatory pathway involves CDPH review and approval of the specific technology, local LEA (Local Enforcement Agency) coordination, and compliance with the facility's existing Medical Waste Management Plan. We have navigated this process and can guide clients through it.
Cost Savings and Risk Reduction
The financial case for on-site treatment is straightforward:
Eliminated transportation costs. No scheduled pickups by a permitted hauler. No fuel surcharges. No per-container transport fees. For facilities generating significant waste volumes, transportation is often the largest single line item on their disposal invoice.
Reduced storage requirements. Waste treated on-site does not need to accumulate in storage. California allows small quantity generators to store medical waste for up to 90 days before pickup, but most facilities want it out faster. On-site treatment can happen daily, eliminating the need for large, dedicated waste storage areas.
Reduced liability. Every hour that infectious waste sits in a storage room or rides in a truck on a public highway is an hour of exposure , regulatory, legal, and reputational. On-site treatment eliminates the transit chain entirely. Your waste never leaves your property in an infectious state.
90% volume reduction. The shredded output takes up roughly one-tenth the space of the original waste. Even if you are disposing of the treated material as municipal waste (before the recycling step), your dumpster costs drop dramatically.
Revenue potential from recycled material. Sorted, virgin-grade plastic has commodity value. While recycling revenue fluctuates with market pricing, it represents a cost offset that traditional disposal never provides. You are turning a pure expense into a partial recovery.
Frequently Asked Questions
Is the EnvoMed 80 approved for use in California?
The EnvoMed 80 achieves STAATT Level IV sterilization, the highest standard recognized by CDPH for alternative medical waste treatment technologies. California's Medical Waste Management Act (HSC Section 117960) requires that treatment methods be approved by CDPH. The system's Level IV performance exceeds the minimum Level III threshold for CDPH approval of alternative treatment technologies.
What is STAATT Level IV and why does it matter?
STAATT stands for State and Territorial Association on Alternate Treatment Technologies. STAATT Level IV is the highest sterilization standard, requiring a minimum 6 LOG10 (99.9999%) reduction of bacterial spores in both solid and liquid waste phases. Most autoclaves achieve Level III. The EnvoMed 80 achieves Level IV , meaning it kills a broader range of organisms more completely than the standard autoclave approach used by most centralized treatment facilities.
How much space does the EnvoMed 80 require?
The system requires a ventilated room of approximately 3 by 5 meters (roughly 10 by 16 feet). Infrastructure requirements include standard electrical supply, water connection, pressurized air, and floor drainage. No specialized HVAC, no boiler room, and no stack or chimney. Most healthcare facilities can accommodate the unit in an existing mechanical room or repurposed storage area.
Does on-site treatment replace the need for a permitted medical waste hauler?
For the biohazardous waste stream, yes. Waste treated on-site by the EnvoMed 80 is rendered non-infectious and can be disposed of as regular municipal solid waste. You would still need permitted haulers for waste streams the EnvoMed does not treat: pharmaceutical waste, chemotherapy waste, radioactive materials, and pathological waste requiring incineration. BAC manages all of these streams as part of our full-service compliance programs.
Can the recycled plastic really be virgin-grade quality?
Yes. The plastics processed through the EnvoMed 80 are sterilized to Level IV, shredded to uniform particle size, and then sorted by resin type. Domestic recycling processors can convert these sorted resin streams into pellets that meet virgin-grade specifications. The key is proper sorting , which is why we developed specific work instructions for resin identification and separation. Unsorted mixed plastic cannot achieve virgin grade. Sorted, sterilized single-resin streams can.
How does this affect my ESG reporting?
On-site treatment with recycling integration dramatically improves every sustainability metric that matters for ESG disclosure: waste diversion rate increases (material recycled instead of landfilled), Scope 3 transportation emissions drop to zero for the treated stream, and you gain documented circular economy outcomes with full chain-of-custody verification. All data flows into your NETZERO360 dashboard and is ready for SB 253, SB 261, and investor-facing ESG reports.
What Comes Next
The EnvoMed 80 at our Fairfield facility is the first deployment of what we intend to be a scalable model. As we validate throughput, refine sorting work instructions, and build relationships with downstream recycling processors, we are building the operational playbook for other facilities to follow.
If your facility generates medical waste and you are tired of paying a national hauler to truck it across the state and landfill it, we should talk. On-site treatment with full circularity is not a concept anymore. It is running in Fairfield right now.
Contact BayArea Compliance at 833-247-OSHA or request a free waste analysis to see how the EnvoMed 80 and NETZERO360 can transform your facility's waste management from a pure cost center into a sustainability asset.